RecruitingCystic Fibrosis-related DiabetesCystic Fibrosis

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)

Sponsor: University of Kansas Medical Center

✓ 1. Age \>18 years with a prior diagnosis of CF.
✓ 2. Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor or vanzacaftor/tezacaftor/deutivacaftor for 30 days prior to day 0
✓ 3. Diagnosis of CFRD with evidence of continued glucose intolerance at least 6 months after starting qualifying modulator therapy will be based upon one of the following:
✓ 1. Insulin use
✓ 2. Hemoglobin A1C \>6.5%
✓ 3. Fasting glucose \>126 mg/dl
✓ 4. Non-fasting glucose \>200 mg/dl (random or as part of a 2-hr OGTT)

✕ 1. Prior lung or liver transplant
✕ 2. Use of supplemental oxygen
✕ 3. BMI \<18
✕ 4. CF pulmonary exacerbation requiring hospitalization or intravenous antibiotics in the preceding 30 days
✕ 5. Systemic corticosteroid or regular non-steroidal anti-inflammatory use in the preceding 30 days
✕ 6. Cardiac, renal (creatinine clearance \<45 mL/minute), neurologic, psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in the study
✕ 7. Alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase \>1.5X the upper limit of normal; bilirubin \>3 mg/dL
✕ 8. Taking medications that interact with metformin.

Kansas City

Source: ClinicalTrials.gov · NCT04530383 · last updated 2026-04-15